Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fermelanta, Inc.
Nonoichi, Ishikawa, Japanfermelanta.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Fermelanta has developed a proprietary technology enabling the introduction and balanced expression of more than 20 biosynthetic genes into E. coli for efficient production of rare plant-derived compounds. The company has achieved practical yields (>1g/L) for certain target molecules and is focused on scaling up production for pharmaceutical and cosmetic applications[4][5].
- Therapeutic areas
- OtherDermatologyMetabolic Disorders
- Modalities
- Microbial fermentation of plant secondary metabolites (e.g., alkaloids, cannabinoids)
- Industry
- Non-Drug Biotech
Beyond the preview
Go deeper on Fermelanta, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fermelanta, Inc..